Healthcare Reform
Obamacare: Gauging the Rx Industry Reaction
Amidst a US Congress that took a number of “nonessential” federal programs and services offline on Monday night, the Obamacare health insurance exchanges are officially up and running. Tom Norton surveys his Rx colleagues to gauge their mood and overall outlook on what it will mean to their companies. ...Read more
Healthcare Reform
Government Shutdown Halts FDA Product Submissions and Other Functions
Planning to submit to the FDA today? Think again. The agency put a forced pause on key services and functions – and furloughed 6,620 FDA employees – as a result of Monday night's government shutdown. Ben Comer reports. ...Read more
Social Media & Marketing
The New Face of Big Pharma Marketing
Doing deals with storytellers could be as important for pharma as collaborating with research scientists, writes Peter Houston.
...Read more
Video
Developing an Aggregate Spend Database: A Lesson from Pfizer
In this, the latest episode of Pharm Exec TV, George Mina, Pfizer's Director/TL-Data Strategy & Reconciliation-Transparency Medical Division - External Medical Communications, on the challenges of implementing the Physician Payment Sunshine Act for pharmaceutical companies. ...Read more
Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format. Tune In Now.
Regulatory
Congress Clarifies Drug Compounding, Tracking Policies
Public outrage over deaths from contaminated injectables produced by large compounding pharmacies, along with rising concerns about counterfeit and unauthorized drugs entering the U.S. market, has managed to lift the stalemate on Capitol Hill long enough to generate agreement on reform legislation. Jill Wechsler reports. ...Read more
New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle. Download Now.
Specialty Medicines
Building an Effective Rare Diseases Business Model
What are the current obstacles to be overcome and the opportunities to be had in rare disease treatment development and commercialization. Nathan J. Dowden reports. ...Read more
New eBook
The Best of the Successful Product Manager's Handbook Volume IV
In the fourth volume of this four-volume set from the pages of Pharmaceutical Executive, you'll arm yourself with information and expert accounts to fortify your marketing plans against both the unexpected and the inevitable ...Read more
|
